Corrective action was not adequately taken to eliminate the cause of nonconformities in order to prevent recurrence.
Inspection Record
Snap Diagnostics, LLC. — FDA 483 Findings
Inspectors Shuana H XiongThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Procedures to define the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product were not adequately documented.
One or more processes for risk management in product realization have not been adequately documented.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- BioSensics LLC2026-02-09 · US FDASimilar to finding 1 Corrective action was not adequately taken to eliminate the cause of nonconformities in order to prevent recurrence.
- Collaborative Care Diagnostics, LLC2026-02-09 · US FDASimilar to finding 3 One or more processes for risk management in product realization have not been adequately documented.
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.